(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
6 August 2009 (06.08.2009)

PCT

(10) International Publication Number
WO 2009/095789 A1

(51) International Patent Classification:
*C07D 487/04* (2006.01) *A61P 25/00* (2006.01)
*A61K 31/519* (2006.01)

(21) International Application Number:
PCT/IB2009/000324

(22) International Filing Date: 27 January 2009 (27.01.2009)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
08290074.7 29 January 2008 (29.01.2008) EP

(71) Applicants *(for all designated States except US)*: **SANOFI-AVENTIS** [FR/FR]; 174 avenue de France, F-75013 Paris (FR). **MITSUBISHI TANABE PHARMA CORPORATION** [JP/JP]; 2-10, Dosho-machi 3-chome, Chuo-ku, Osaka-shi, Osa, ka 541-8505 (JP).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **FAYOL, Aude** [FR/FR]; c/o Sanofi-Aventis, Département Brevets, 174 avenue de France, F-75013 Paris (FR). **LOCHEAD, Alistair** [GB/FR]; c/o Sanofi-Aventis, Département Brevets, 174 avenue de France, F-75013 Paris (FR). **SAADY, Mourad** [FR/FR]; c/o Sanofi-Aventis, Département Brevets, 174 avenue de France, F-75013 Paris (FR). **VACHE, Julien** [FR/FR]; c/o Sanofi-aventis, Département Brevets, 174 avenue de France, F-75013 Paris (FR). **YAICHE, Philippe** [FR/FR]; c/o Sanofi-Aventis, Département Brevets, 174 avenue de France, F-75013 Paris (FR).


(74) Agent: **MOREL-PECHEUX, Muriel**; Sanofi-aventis, Département Brevets, 174 avenue de France, F-75013 PARIS Paris (FR).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

(54) Title: SUBSTITUTED ARYLAMIDE DIAZEPINOPYRIMIDONE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES CAUSED BY ABNORMAL ACTIVITY OF GSK3-BETA




(I)

(57) Abstract: A pyrimidone derivative represented by formula (I) or a salt thereof, or a solvate thereof or a hydrate thereof: wherein: Y represents two hydrogen atoms, a sulphur atom, an oxygen atom or a $C_{1-2}$ alkyl group and a hydrogen atom; Z represents a bond, an oxygen atom, a nitrogen atom substituted by a hydrogen atom or a $C_{1-3}$ alkyl group, a sulphur atom, a methylene group optionally substituted by one or two groups chosen from a $C_{1-6}$ alkyl group, a hydroxyl group, a $C_{1-6}$ alkoxy group, a $C_{1-2}$ perhalogenated alkyl group or an amino group; R1 represents a 2, 3 or 4-pyridine ring or a 2, 4 or 5-pyrimidine ring, the ring being optionally substituted by a $C_{1-6}$ alkyl group, a $C_{1-6}$ alkoxy group or a halogen atom; R2 represents a hydrogen atom, a $C_{1-6}$ alkyl group or a halogen atom; R3 represents a benzene ring or a naphthalene ring; the rings being optionally substituted R4 represents a hydrogen atom, a $C_{1-6}$ alkyl group, a $C_{3-7}$ cycloalkyl group, a $C_{3-7}$ cycloalkyl-$C_{1-6}$ alkyl group, a COO ($C_{1-6}$-alkyl) group, these group being optionally substituted; R5 represents a hydrogen atom or a $C_{1-6}$ alkyl group and n represents 0 to 3 and their therapeutic use for the treatment of neurodegenerative diseases caused by abnormal activity of GSK3β.

WO 2009/095789 A1